Press Releases Theranexus

Equities

ALTHX

FR0013286259

Real-time Euronext Paris Other stock markets 08:35:05 2024-04-29 am EDT			5-day change	1st Jan Change
1.155 ^EUR	+1.76%		+10.53%	+3.12%

Apr. 19	Theranexus: share price rises following promising trial results	CF
Mar. 11	Theranexus: CEO takes over as Chairman of the Board	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theranexus : Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide	Apr. 23	AT
Theranexus : Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1	Apr. 18	AT
Theranexus : THERANEXUS ANNOUNCES APPOINTMENT OF MATHIEU CHARVÉRIAT AS BOARD OF DIRECTORS CHAIRMAN	Mar. 11	AT
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS	Feb. 14	AT
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023	23-10-17	AT
Theranexus : Theranexus : Highly Promising 12-month results in the Phase I/II trial of Batten-1	23-09-29	AT
Theranexus : THERANEXUS ANNOUNCES FIRST HALF 2023 FINANCIAL RESULTS	23-09-28	AT
Theranexus : Theranexus raises around 3.1 million euros in fundraising	23-07-12	AT
Theranexus : Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in Batten disease (CLN3)	23-06-14	AT
Theranexus : Theranexus and BBDF win FDA approval on efficacy endpoints for the Phase III trial to evaluate Batten-1 in CLN3 Batten disease	23-05-09	AT
Theranexus : THERANEXUS PUBLISHES ITS 2022 FULL-YEAR RESULTS AND PRESENTS AN UPDATE ON ITS PROGRAMS	23-04-12	AT
Theranexus : THERANEXUS, BBDF AND CARDIFF UNIVERSITY PRESENT THEIR NOVEL RESEARCH ON BATTEN-1 AND BATTEN DISEASE AT WORLDSYMPOSIUM 2023	23-02-20	AT
Theranexus : AISTROSIGHT: NEW JOINT PROJECT TEAM BETWEEN THERANEXUS, INRIA, CLAUDE BERNARD UNIVERSITY LYON 1 AND HOSPICES CIVILS DE LYON TARGETING RARE NEUROLOGICAL DISEASES	23-02-10	AT
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2022 AND ANNOUNCES ORGANIZATIONAL CHANGES	23-01-18	AT
Theranexus : Présentation JPM / Biotech showcase / Sachs Forum	23-01-05	PU
Theranexus : New advance to the Theranexus and BBDF Batten-1 program for juvenile Batten disease (CLN3)	23-01-05	AT
Theranexus : THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2023	22-12-21	AT
Theranexus : THERANEXUS ANNOUNCES PARTICIPATION IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 9-12, 2023 IN SAN FRANCISCO	22-12-20	AT
Theranexus : THERANEXUS AND BBDF PRESENT PROGRESS ON THE BATTEN-1 PROGRAM AT THE TRANSLATIONAL RESEARCH CONFERENCE FOR THE MANAGEMENT OF NCLS ON 3 AND 4 NOVEMBER, 2022 IN CHICAGO	22-11-02	AT
Theranexus : THERANEXUS AND INSERM TRANSFERT SIGN A STRATEGIC ALLIANCE TO IDENTIFY ADVANCED THERAPY DRUG CANDIDATES FOR RARE NEUROLOGICAL DISEASES	22-10-20	AT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Theranexus

Equities

ALTHX

FR0013286259

Press Releases

Filters